Business Context and Reporting Period
Company: Retractable Technologies, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2007
Business Overview: The Company designs, develops, manufactures, and markets patented safety medical products, primarily the VanishPoint® safety syringe line, designed to prevent needlestick injuries. The Company operates in a market dominated by Becton Dickinson (BD), against which it is currently litigating for antitrust violations and patent infringement. International sales grew to 18.4% of total revenue in 2007.
Key Financial Metrics
| Metric | 2007 | 2006 | 2005 |
|---|---|---|---|
| Total Sales | $26,290,000 | $25,325,000 | $24,235,000 |
| Gross Profit | $7,990,000 | $7,546,000 | $8,806,000 |
| Gross Margin | 30.4% | 29.8% | 36.3% |
| Operating Loss | $(9,946,000) | $(6,715,000) | $(2,877,000) |
| Net Loss | $(6,948,000) | $(3,870,000) | $(1,238,000) |
| Net Loss Per Share (Basic/Diluted) | $(0.35) | $(0.23) | $(0.12) |
| Cash and Cash Equivalents | $40,507,000 | $46,815,000 | $52,514,000 |
| Total Assets | $64,330,000 | $70,795,000 | $73,756,000 |
| Long-Term Debt | $3,747,000 | $4,137,000 | $4,351,000 |
| Preferred Dividends in Arrears | $12,500,000 | $12,200,000 | N/A |
Material Changes vs. Prior Period
- Revenue Growth: Total sales increased 3.8% to $26.3 million, driven primarily by a 56.5% increase in international sales ($4.8 million vs. $3.1 million in 2006). Domestic sales declined slightly.
- Discontinued Reimbursements: The Company received $0 in reimbursed discounts in 2007, compared to $4.4 million in 2006. This program, established via a prior settlement with BD, expired in 2006.
- Operating Expenses: Total operating expenses increased 25.8% to $17.9 million. This was primarily due to a significant increase in General and Administrative costs (driven by legal fees for ongoing litigation) and higher R&D costs for new product validation.
- Liquidity Decline: Cash and cash equivalents decreased by approximately $6.3 million during the year due to operating losses and increased legal expenses.
- Inventory: Inventory levels increased to $7.0 million from $6.4 million, with a corresponding increase in the inventory reserve to $205,600.
Guidance, Outlook, Risks, and Contingencies
- Legal Proceedings: The Company is engaged in significant litigation against BD (antitrust, patent infringement, false advertising) with a trial scheduled for March 2009. Legal expenses are expected to remain high until resolution. The Company is also defending against patent infringement claims from BD/MDC and MedSafe Technologies.
- Market Access: Management states it is blocked from significant market access by BD's monopolistic practices and exclusive contracts with Group Purchasing Organizations (GPOs). The Company relies on international markets and alternate care facilities for growth.
- Licensing: A licensing agreement with Baiyin Tonsun Medical Device Co., Ltd. (BTMD) in China expires May 13, 2008. Royalties expected in 2007 were not received due to infrastructure delays; the Company expects royalties to begin once Chinese government requirements are met.
- Capital Expenditures: The Company is finalizing a loan of approximately $4.2 million to fund a warehouse expansion and new Clean Room.
- Patent Expiration: The principal U.S. patent protecting the core technology is set to expire in May 2015.
- Stock Price: The Company notes its stock price sometimes falls below the $2.00 listing standard for the American Stock Exchange, posing a risk of delisting.
Investor Verification Checklist
- Litigation Status: Verify the current status and potential financial impact of the lawsuit against BD and the counterclaims filed by BD and MedSafe.
- BTMD Royalties: Confirm whether the Chinese licensing partner (BTMD) has met government requirements and when royalty payments are expected to commence.
- Market Share: Assess the Company's ability to penetrate the U.S. hospital market given the dominance of BD and the reliance on GPOs.
- Cash Burn Rate: Monitor the rate of cash depletion given the operating losses and high legal costs, and the sufficiency of current reserves ($40.5 million) to fund operations until litigation resolution or new revenue streams materialize.
- Preferred Stock Arrears: Review the $12.5 million in cumulative preferred dividends in arrears and the implications for common shareholders regarding liquidation preferences and voting rights.